Terms: = Gastric cancer AND PRF1, P14222, PFP, P1, MGC65093, HPLH2, FLH2, ENSG00000180644, 5551 AND Clinical Outcome
8 results:
1. Cytolytic activity score as a biomarker for antitumor immunity and clinical outcome in patients with gastric cancer.
Hu Q; Nonaka K; Wakiyama H; Miyashita Y; Fujimoto Y; Jogo T; Hokonohara K; Nakanishi R; Hisamatsu Y; Ando K; Kimura Y; Masuda T; Oki E; Mimori K; Oda Y; Mori M
Cancer Med; 2021 May; 10(9):3129-3138. PubMed ID: 33769705
[TBL] [Abstract] [Full Text] [Related]
2. Prognostic value of expression of Kit67, p53, TopoIIa and GSTP1 for curatively resected advanced gastric cancer patients receiving adjuvant paclitaxel plus capecitabine chemotherapy.
Zha Y; Cun Y; Zhang Q; Li Y; Tan J
Hepatogastroenterology; 2012; 59(117):1327-32. PubMed ID: 22534478
[TBL] [Abstract] [Full Text] [Related]
3. Genetic polymorphism of GSTP1: prediction of clinical outcome to oxaliplatin/5-FU-based chemotherapy in advanced gastric cancer.
Li QF; Yao RY; Liu KW; Lv HY; Jiang T; Liang J
J Korean Med Sci; 2010 Jun; 25(6):846-52. PubMed ID: 20514304
[TBL] [Abstract] [Full Text] [Related]
4. Polymorphisms in p53, GSTP1 and XRCC1 predict relapse and survival of gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy.
Huang ZH; Hua D; Du X
Cancer Chemother Pharmacol; 2009 Oct; 64(5):1001-7. PubMed ID: 19247656
[TBL] [Abstract] [Full Text] [Related]
5. Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer.
Kwon HC; Roh MS; Oh SY; Kim SH; Kim MC; Kim JS; Kim HJ
Ann Oncol; 2007 Mar; 18(3):504-9. PubMed ID: 17322540
[TBL] [Abstract] [Full Text] [Related]
6. Determinants of chemosensitivity in gastric cancer.
Park DJ; Lenz HJ
Curr Opin Pharmacol; 2006 Aug; 6(4):337-44. PubMed ID: 16777480
[TBL] [Abstract] [Full Text] [Related]
7. Polymorphisms of glutathione S-transferases (GST) and thymidylate synthase (TS)--novel predictors for response and survival in gastric cancer patients.
Goekkurt E; Hoehn S; Wolschke C; Wittmer C; Stueber C; Hossfeld DK; Stoehlmacher J
Br J Cancer; 2006 Jan; 94(2):281-6. PubMed ID: 16317430
[TBL] [Abstract] [Full Text] [Related]
8. Genomic alterations in primary gastric adenocarcinomas correlate with clinicopathological characteristics and survival.
Weiss MM; Kuipers EJ; Postma C; Snijders AM; Pinkel D; Meuwissen SG; Albertson D; Meijer GA
Cell Oncol; 2004; 26(5-6):307-17. PubMed ID: 15623941
[TBL] [Abstract] [Full Text] [Related]
